^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

    Published date:
    11/04/2020
    Excerpt:
    Among the 17 genes with at least 5% prevalence, only TP53 mutations were associated with worse response. TP53 mutations increased monotonically with worse outcomes...Ninety-three percent of patients (13 of 14 patients) with TP53 mutations had poor cytogenetics....Patients with TP53 mutations at AML diagnosis were associated with lower response rates to induction chemotherapy...
    DOI:
    https://doi.org/10.1182/blood-2020-138561